Iain Stuart
CIK 1727756 · CHIEF SCIENTIFIC OFFICER · last filed 2026-07-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FOMX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
REHOVOT, L3 76704
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. (VYNE) Delisted | CHIEF SCIENTIFIC OFFICER | 1,919 | $28.56 | $54.8K | $0 | 30 | 2026-07-24 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Chief Scientific Officer | 291,018 | — | — | $0 | 5 | 2020-07-02 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Chief Scientific Officer | 103,636 | — | — | -$27.1K | 9 | 2020-02-24 |
Recent Filings · Page 3 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-04 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −3,469 | -$2.3K | EDGAR |
| 2022-03-18 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2022-01-04 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −1,250 | -$1.3K | EDGAR |
| 2021-10-01 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −1,480 | -$2.1K | EDGAR |
| 2021-09-03 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | +60,859 | $0 | EDGAR |
| 2021-07-02 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −3,083 | -$10.8K | EDGAR |
| 2021-04-02 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −1,945 | -$13.3K | EDGAR |
| 2021-02-24 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | +29,213 | $0 | EDGAR |
| 2021-01-05 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −2,378 | -$3.8K | EDGAR |
| 2020-10-02 | VYNE Therapeutics Inc. (VYNE) Delisted | Tax (F) | −2,378 | -$3.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.